Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline

Ariane Fraiche; Andrew Wang

doi:10.1007/s11886-016-0751-8

Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline

Curr Cardiol Rep. 2016 Jul;18(8):70. doi: 10.1007/s11886-016-0751-8.

Authors

Ariane Fraiche¹, Andrew Wang²

Affiliations

¹ Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA.
² Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA. a.wang@duke.edu.

PMID: 27294414
DOI: 10.1007/s11886-016-0751-8

Abstract

Since publication of the 2011 American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy (HCM), more recent studies offer greater insights about this condition. With increased recognition of the role of sarcomere protein mutations and myocardial structural abnormalities in the pathophysiology of this disease, new evidence offers potential improvements for the management of patients with HCM. In this review of studies published since 2011, we highlight several studies that may impact diagnostic considerations, risk stratification, and treatment of symptoms in HCM.

Keywords: Cardiac magnetic resonance imaging; Hypertrophic cardiomyopathy; Risk stratification; Sudden cardiac death; Treatment.

Publication types

Review

MeSH terms

American Heart Association
Atrial Fibrillation / epidemiology*
Cardiology
Cardiomyopathy, Hypertrophic / complications*
Cardiomyopathy, Hypertrophic / diagnostic imaging*
Cardiomyopathy, Hypertrophic / therapy*
Death, Sudden, Cardiac / epidemiology*
Humans
Magnetic Resonance Imaging
Myocardium / pathology
Practice Guidelines as Topic
Risk Assessment
Risk Factors
United States